When is risk-reducing endocrine therapy recommended for lobular carcinoma in situ?

Lobular carcinoma in situ, or LCIS, is an abnormal change in breast lobules rather than an invasive cancer. It can signal a higher future risk in either breast, so clinicians may discuss closer breast surveillance, medicine, and sometimes surgery depending on the findings. The choice of endocrine therapy depends on the LCIS subtype, biopsy details, age, menopause, family history, other risk factors, and existing health conditions.

Review the pathology report with a breast specialist and ask whether the tissue diagnosis is classic or pleomorphic LCIS. Share medicines, clotting history, bone health, menstrual history, and plans for pregnancy. Discuss the expected effect on risk, hot flushes, mood, sexual health, bones, and blood vessels. Keep recommended breast imaging appointments even if you start endocrine therapy.

Report a new breast lump, nipple inversion or discharge, skin change, or a persistent local symptom to a clinician for assessment. If taking endocrine therapy, seek prompt advice for unexplained vaginal bleeding, severe leg pain or swelling, chest pain, sudden breathlessness, or a new neurological symptom. Use emergency services for severe breathing trouble, collapse, or possible stroke.

What type of LCIS was found, and what does it mean for both breasts? What medicine could I use and for how long? Which side effects matter most with my medical history? What surveillance plan will I follow? What alternatives are reasonable if I decide against medicine?